Proteome Share News (PRM)
PRM Share
PRM Share
PRM Share
PRM Share
PRM
PRM Share
PRM Level 2
PRM Live
PRM Broker
PRM Directors
PRM Financial
PRM
PRM Short
PRM
Last checked at -
Thu, 09th Aug 2018 14:50
LONDON (Alliance News) - Proteome Sciences said Thursday that Vulpes Life Sciences Fund purchased 1.4 million shares in the company on Tuesday at 3.50 pence each.
Vulpes now has a 19.6% holding in the company, equivalent to an interest in 57.8 million shares.
Martin Diggle, director of both Vulpes Investment Management and Proteome, now also holds a 19.6% interest in Proteome.
Shares in Proteome were down 2.5% at 3.558 pence each on Thursday.
AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov
Read moreDrug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha
Read more
The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv
Read moreDrug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin
Read moreProteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services
Read moreMedical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall
Read moreCity sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European
Read moreBiotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility
Read morePharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear
Read morePharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive
Read moreShares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f
Read moreBiomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010
Read more
Last checked at